[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 1966

Acetazolamide and Outflow Facility

Author Affiliations

New York
From the Department of Surgery (Ophthalmology) of The New York Hospital-Cornell Medical Center, New York. Dr. Galin is a Career Scientist, Health Research Council, New York City, and Dr. Harris is a Postdoctoral Fellow, National Council to Combat Blindness.

Arch Ophthalmol. 1966;76(4):493-497. doi:10.1001/archopht.1966.03850010495006

The carbonic anhydrase inhibitors are the drugs most useful clinically in reducing aqueous flow and lowering intraocular pressure.1-3 Their hypotensive effect is greater in the hypertensive eye than in the normal, and in the latter has been reported to be accompanied by a compensatory reduction in outflow facility.3,4 Mechanisms other than a reduction in aqueous flow have been postulated for these agents, but have received little support.5,6 No studies have come to our attention indicating that these agents might primarily influence outflow facility.

This communication reports a small series of patients in whom significant, reproducible improvement in outflow facility and reduction in intraocular pressure resulted after therapy with acetazolamide alone. No effect on aqueous flow was discernible. Because of the significant improvement in outflow facility unobtainable by any other form of therapy, all these patients have been maintained solely on treatment with this compound for more than

First Page Preview View Large
First page PDF preview
First page PDF preview